Integrin targeting ligands and uses thereof
US-12582718-B2 · Mar 24, 2026 · US
This page is not indexed by search engines while we improve data quality.
Nicholas Anthony patents
Nicholas Anthony is listed as an inventor on 39 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Nicholas Anthony |
| Total patents | 39 |
| First publication | Jan 10, 2019 |
| Latest publication | Mar 24, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use
US-2026078375-A1 · Mar 19, 2026 · US
RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use
US-2026009037-A1 · Jan 8, 2026 · US
RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use
US-2025376688-A1 · Dec 11, 2025 · US
RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
US-12486502-B2 · Dec 2, 2025 · US
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
US-12365897-B2 · Jul 22, 2025 · US
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
US-12221610-B2 · Feb 11, 2025 · US
Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products
US-2025034578-A1 · Jan 30, 2025 · US
RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use
US-2025034577-A1 · Jan 30, 2025 · US
Alpha-v beta-6 integrin ligands and uses thereof
US-12173086-B2 · Dec 24, 2024 · US
Recent patents
Latest publications not already listed above.
RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use
US-2024392292-A1 · Nov 28, 2024 · US
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
US-12054718-B2 · Aug 6, 2024 · US
RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
US-11912997-B2 · Feb 27, 2024 · US
RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use
US-2024026363-A1 · Jan 25, 2024 · US
RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use
US-2023416737-A1 · Dec 28, 2023 · US
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
US-11845937-B2 · Dec 19, 2023 · US
RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use
US-2023265437-A1 · Aug 24, 2023 · US
RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use
US-2023265430-A1 · Aug 24, 2023 · US
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
US-2023139166-A1 · May 4, 2023 · US
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
US-2023125671-A1 · Apr 27, 2023 · US
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
US-11629349-B2 · Apr 18, 2023 · US
RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use
US-2023013022-A1 · Jan 19, 2023 · US
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
US-2023013224-A1 · Jan 19, 2023 · US
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
US-11549112-B1 · Jan 10, 2023 · US
RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
US-2023002767-A1 · Jan 5, 2023 · US
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
US-2023002773-A1 · Jan 5, 2023 · US
RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use
US-2022396791-A1 · Dec 15, 2022 · US
RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use
US-2022204976-A1 · Jun 30, 2022 · US
RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
US-2022090077-A1 · Mar 24, 2022 · US
Alpha-v beta-6 integrin ligands and uses thereof
US-2022024975-A1 · Jan 27, 2022 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Arrowhead Pharmaceuticals Inc | 39 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C12N2310/14 | 39 |
| C12N2310/351 | 34 |
| C12N2310/315 | 32 |
| C12N2320/32 | 29 |
| C12N15/113 | 28 |